Risk Assessment of Combined Detection of Lipoprotein Associated Phospholipase A2 and Cystatin C for Lupus Nephritis in Patients with Systemic Lupus Erythematosus
10.3969/j.issn.1671-7414.2017.04.002
- VernacularTitle:血清脂蛋白相关磷脂酶A2和胱抑素C联合检测对SLE患者并发狼疮性肾炎的风险评估
- Author:
Kun WANG
;
Xingwang JIA
;
Jin DONG
;
Guangtao YAN
- Keywords:
lipoprotein-related phospholipase A2;
cystatin C;
systemic lupus erythematosus;
lupus nephritis
- From:
Journal of Modern Laboratory Medicine
2017;32(4):6-8,11
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of combinedevaluation of serum lipoprotein associated phospholipase A2 (LP-PLA2) and cystatin C (CysC) on systemic lupus erythematosus (SLE) patients with lupus erythematosus.Methods A total of 177 patients with SLE were enrolled in the General Hospital of People's Liberation Army from June 2000 to February 2017,87 cases in lupus group (SLE group),90 cases in lupus nephritis group (LN group),60 cases in healthy control group.The concentration of LP-PLA2 and CysC were measured.The ROC curves was established for estimation of the cutoff values of two indexes in SLE patients with LN,and the diagnostic efficacy of different diagnostic criteria was compared.Results The LP-PLA2 and CysC concentration in the LN group were higher than those in the SLE group (Z=-2.512,-5.688,all P＜0.05).The cutoff value of LP-PLA2 was 245.5 U/L and the cutoff value of CysC was 1.235 mg/L on the risk assessment of in SLE patients with LN.When using the parallel method for combined LP-PLA2 and CysC to evaluate the risk of LN,the sensitivity and negative predictive value would be significantly improved (x2 =9.461,4.377,all P＜ 0.05),the efficiency was better.Conclusion Parallel assessment of serum LP-PLA2 and CysC have clinical value on assessment of the risk of LN in SLE patients.
